AstraZeneca PLC (AZN)
| Market Cap | 303.56B +43.0% |
| Revenue (ttm) | 58.74B +8.6% |
| Net Income | 10.23B +45.3% |
| EPS | 6.54 +45.3% |
| Shares Out | 1.55B |
| PE Ratio | 29.69 |
| Forward PE | 19.02 |
| Dividend | $3.20 (1.66%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 2,178,833 |
| Open | 195.21 |
| Previous Close | 194.81 |
| Day's Range | 191.81 - 196.64 |
| 52-Week Range | 131.03 - 212.71 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsNews
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment
AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment
Germany risks missing out on new drugs, AstraZeneca CEO tells paper
AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending on ...
AstraZeneca I CAN Phase III Interim Analysis Meets Primary Goal
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Tuesday said an interim analysis of its Phase III I CAN study showed that Ultomiris met the primary endpoint in adults with immunoglobulin A nephropathy...
AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease
AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris met the main goal of a late stage trial, showing a reduction in protein found in the urine of patients with a rare ki...
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab
Tozorakimab (AZN) Shows Promise in COPD Treatment in Phase III Trial
Tozorakimab (AZN) Shows Promise in COPD Treatment in Phase III Trial
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinica...
AstraZeneca Says Tozorakimab Meets Main Goal In Phase III COPD Trial
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Monday said its pivotal Phase III MIRANDA trial of tozorakimab in patients with Chronic Obstructive Pulmonary Disease met its primary endpoint, demonstr...
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups
AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups of chronic obstruc...
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by President Trump
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by President Trump
AstraZeneca (AZN) Advances Portfolio with Strategic Update
AstraZeneca (AZN) Advances Portfolio with Strategic Update
Only Two Days Away – Don't Miss it! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy's 2026 New York Summit. Be a Part of It. Register Now.
FAIRFIELD, Conn., April 14, 2026 (GLOBE NEWSWIRE) -- HMG Strategy, the world's leading platform for inspiring technology executives to lead boldly and shape the future of business, will bring Big Appl...
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative 'personalized off-the-shelf' immunotherapy toward clinical development
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard's lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that trigger...
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
Once the go-to location for global drugmakers, Europe is losing market share to aggressive U.S. trade policies and China's growth as a biotech hub. Europe's share of global R&D has been cut in half ov...
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
AstraZeneca PLC: Result of AGM
9 April 2026 Results of Annual General Meeting held on 9 April 2026 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, ...
The Zacks Analyst Blog Highlights AstraZeneca, HSBC, Walt Disney, Oak Valley Bancorp and BV Financial
AstraZeneca (AZN) leads Zacks Research highlights with strong drug growth and pipeline momentum, while HSBC and Disney navigate costs and competition.
Top Research Reports for AstraZeneca, HSBC & Walt Disney
AstraZeneca's strong drug portfolio and pipeline fuel growth targets, while HSBC restructures and Disney balances streaming gains against rising costs.
AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals
Hyderabad: AstraZeneca Pharma India, a subsidiary of British-Swedish pharma giant AstraZeneca Plc, has signed a memorandum of understanding with the T.
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices
New tax will hit branded drugs and active ingredients while exempting generics for at least one year
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import Duties
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import Duties
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...